Request for Nominations for Voting Members on Public Advisory Committee, Science Board to the Food and Drug Administration, 72954-72955 [2011-30415]
Download as PDF
pmangrum on DSK3VPTVN1PROD with NOTICES
72954
Federal Register / Vol. 76, No. 228 / Monday, November 28, 2011 / Notices
Date and Time: The meeting will be
held on January 6, 2012, from 9 a.m. to
4 p.m.
Location: FDA White Oak Campus,
10903 New Hampshire Ave., Building
31 Conference Center, the Great Room
(rm. 1503), Silver Spring, MD 20993–
0002.
For those unable to attend in person,
the meeting will also be webcast. The
link for the webcast is available at
https://collaboration.fda.gov/
scienceboard/. Information regarding
special accommodations due to a
disability, visitor parking, and
transportation may be accessed at:
https://www.fda.gov/
AdvisoryCommittees/default.htm; under
the heading ‘‘Resources for You,’’ click
on ‘‘Public Meetings at the FDA White
Oak Campus.’’ Please note that visitors
to the White Oak Campus must enter
through Building 1.
Contact Person: Martha Monser,
Office of the Commissioner, Food and
Drug Administration, 10903 New
Hampshire Ave, Bldg. 32, rm. 4286,
Silver Spring MD 20993–0002, (301)
796–4627, or FDA Advisory Committee
Information Line, 1–(800) 741–8138
(301) 443–0572 in the Washington, DC
area), and follow the prompt to the
desired center or product area. Please
call the Information Line for up-to-date
information on this meeting. A notice in
the Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site and call the
appropriate advisory committee hot
line/phone line to learn about possible
modifications before coming to the
meeting.
Agenda: The Science Board will hear
about and provide input regarding the
two Centers for Excellence in Regulatory
Science and Innovation. The Science
Board will also hear updates regarding
the Scientific Computing/JANUS
program, and FDA’s Scientific Integrity
Policy. FDA’s Modernizing Toxicology
Working Group will present an
overview to the Science Board for input
and discussion. The Center for Drug
Evaluation and Research (CDER) will
provide their response to the May 2011
Subcommittee Report regarding the
Review of the FDA/CDER
Pharmacovigilance Program.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
VerDate Mar<15>2010
15:34 Nov 25, 2011
Jkt 226001
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before December 30, 2011.
Oral presentations from the public will
be scheduled between approximately 1
p.m. and 2 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before
December 22, 2011. Time allotted for
each presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by December 23, 2011.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Ms. Martha
Monser, at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: November 18, 2011.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2011–30416 Filed 11–25–11; 8:45 am]
BILLING CODE 4160–01–P
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0002]
Request for Nominations for Voting
Members on Public Advisory
Committee, Science Board to the Food
and Drug Administration
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug Administration
(FDA) is requesting nominations for
voting members to serve on the Science
Board to the FDA (the Science Board).
FDA has special interest in ensuring
that women, minority groups, and
individuals with disabilities are
adequately represented on advisory
committees and, therefore, encourages
nominations of qualified candidates
from these groups.
DATES: Nominations received on or
before December 28, 2011, will be given
first consideration for membership on
the Science Board. Nominations
received after December 28, 2011, will
be considered for nomination to the
Science Board should nominees still be
needed.
ADDRESSES: All nominations for
membership should be sent
electronically to CV@FDA.HHS.GOV, or
by mail to Advisory Committee
Oversight & Management Staff, 10903
New Hampshire Ave., Bldg. 32, Rm.
5103, Silver Spring, MD 20993–0002.
FOR FURTHER INFORMATION CONTACT:
Regarding all nomination questions for
membership, the primary contact is:
Martha Monser, Office of the Chief
Scientist, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 4286, Silver Spring,
MD 20993–0002, (301) 796–4627, email:
martha.monser@fda.hhs.gov.
Information about becoming a member
on an FDA advisory committee can also
be obtained by visiting FDA’s Web site
by using the following link: https://
www.fda.gov/oc/advisory/default.htm.
SUPPLEMENTARY INFORMATION: FDA is
requesting nominations for voting
members on the Science Board.
I. General Function of the Committee
The Science Board shall provide
advice primarily to the Commissioner of
Food and Drugs (the Commissioner) and
other appropriate officials on both
general and specific scientific and
technical issues as well as emerging
issues within the scientific community.
Additionally, the Science Board will
E:\FR\FM\28NON1.SGM
28NON1
Federal Register / Vol. 76, No. 228 / Monday, November 28, 2011 / Notices
provide advice to the Agency on
keeping pace with technical and
scientific advances in the fields of
regulatory science; on formulating an
appropriate research agenda; and on
upgrading its scientific and research
facilities to keep pace with these
changes. It will also provide the means
for critical review of Agency strategic
science plan and its implementation as
well as of related intramural and
extramural scientific research and
training.
II. Criteria for Voting Members
Members and the Chair are selected
by the Commissioner or designee from
among authorities knowledgeable in the
fields of food safety, nutrition,
chemistry, pharmacology, toxicology,
clinical research, and other scientific
disciplines. Members shall represent
academia and industry. The Science
Board may include one technically
qualified member, selected by the
Commissioner or designee, who is
identified with consumer interests and
is either recommended by either a
consortium of consumer oriented
organizations or other interested
persons. The Science Board may also
include technically qualified federal
members. FDA is currently specifically
seeking persons knowledgeable in the
fields of pharmacology, translational
and clinical medicine, toxicology,
clinical research and related
biostatistics, public health and
epidemiology, international public
health and regulation, product safety,
product manufacturing sciences and
quality or other scientific areas relevant
to FDA regulated products such as
systems biology, advanced scientific
informatics, nanotechnology, food
sciences, medical devices and
combination products.
pmangrum on DSK3VPTVN1PROD with NOTICES
III. Nomination Procedures
Any interested person may nominate
one or more qualified persons for
membership on the Science Board. Self
nominations are also accepted.
Nominations shall include the name of
the committee, complete curriculum
vitae of each nominee, and their current
business address and telephone number
and email address if available.
Nominations must specify the advisory
committee for which the nominee is
recommended. Nominations must also
acknowledge that the nominee is aware
of the nomination, unless self
nominated. FDA will ask potential
candidates to provide detailed
information concerning such matters as
financial holdings, employment, and
research grants and/or contracts.
VerDate Mar<15>2010
15:34 Nov 25, 2011
Jkt 226001
This notice is issued under the
Federal Advisory Committee Act
(5 U.S.C. app. 2) and 21 CFR part 14
relating to advisory committees.
Dated: November 21, 2011.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2011–30415 Filed 11–25–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0828]
Wyeth Pharmaceuticals, Inc.;
Withdrawal of Approval of a New Drug
Application for MYLOTARG
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is withdrawing
approval of a new drug application
(NDA) for MYLOTARG (gemtuzumab
ozogamicin) for Injection, held by
Wyeth Pharmaceuticals, Inc. (Wyeth),
500 Arcola Rd., Collegeville, PA 19426.
Wyeth, now a part of Pfizer, Inc., has
voluntarily requested that approval of
this application be withdrawn, thereby
waiving its opportunity for a hearing.
DATES: Effective November 28, 2011.
FOR FURTHER INFORMATION CONTACT:
David Joy, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 51, Rm. 6254, Silver Spring,
MD 20993–0002, (301) 796–3601.
SUPPLEMENTARY INFORMATION: FDA
approved MYLOTARG (gemtuzumab
ozogamicin) for Injection on May 17,
2000, under the Agency’s accelerated
approval regulations, 21 CFR part 314,
subpart H. MYLOTARG was indicated
for the treatment of patients with CD33positive acute myeloid leukemia in first
relapse who were 60 years of age or
older and who were not considered
candidates for other cytotoxic
chemotherapy. On May 21, 2010, FDA
requested that Wyeth voluntarily
withdraw MYLOTARG from the market,
after results of a required postapproval
clinical trial failed to verify clinical
benefit to patients and raised new
concerns about the drug’s safety. In a
letter dated October 25, 2010, Wyeth
requested that FDA withdraw approval
of NDA 21–174, MYLOTARG
(gemtuzumab ozogamicin) for Injection,
under § 314.150(d) (21 CFR 314.150(d)).
In that letter, Wyeth also waived its
SUMMARY:
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
72955
opportunity for a hearing, provided
under 21 CFR 314.150 and 314.530. In
FDA’s acknowledgment letter of
November 2, 2010, the Agency stated
that a large prospective trial that tested
the addition of MYLOTARG to first-line
chemotherapy for patients with newly
diagnosed acute myelogenous leukemia
failed to verify clinical benefit of
MYLOTARG and raised safety concerns.
FDA also acknowledged that Wyeth
waived its opportunity for a hearing.
Therefore, under sections 505(e) and
506(b)(3) of the Federal Food, Drug, and
Cosmetic Act (FD&C Act) (21 U.S.C.
355(e) and 356(b)(3)) and § 314.150(d),
and under authority delegated by the
Commissioner to the Director, Center for
Drug Evaluation and Research, approval
of NDA 21–174, and all amendments
and supplements thereto, is withdrawn
(see DATES). Distribution of this product
in interstate commerce without an
approved application is illegal and
subject to regulatory action (see sections
505(a) and 301(d) of the FD&C Act (21
U.S.C. 355(a) and 331(d))).
Dated: November 22, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–30473 Filed 11–25–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment
Request: ‘‘Ethical Dilemmas in Surgery
and Utilization of Hospital Ethics
Consultation Service: A Survey’’
In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
Department of Bioethics, the Clinical
Center, the National Institutes of Health
(NIH) will publish periodic summaries
of proposed projects to be submitted to
the Office of Management and Budget
(OMB) for review and approval.
Proposed Collection: Title: Ethical
Dilemmas in Surgery and Utilization of
Hospital Ethics Consultation Service: A
Survey. Type of Information Collection
Request: NEW. Need and Use of
Information Collection: This survey is
intended to collect information about
the ethical dilemmas that surgeons have
faced in their practices over the past
year, and assess their experiences, if
any, with their hospital consultation
services. Specifically, the information
gathered in this study will be valuable
SUMMARY:
E:\FR\FM\28NON1.SGM
28NON1
Agencies
[Federal Register Volume 76, Number 228 (Monday, November 28, 2011)]
[Notices]
[Pages 72954-72955]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-30415]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0002]
Request for Nominations for Voting Members on Public Advisory
Committee, Science Board to the Food and Drug Administration
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) is requesting nominations
for voting members to serve on the Science Board to the FDA (the
Science Board).
FDA has special interest in ensuring that women, minority groups,
and individuals with disabilities are adequately represented on
advisory committees and, therefore, encourages nominations of qualified
candidates from these groups.
DATES: Nominations received on or before December 28, 2011, will be
given first consideration for membership on the Science Board.
Nominations received after December 28, 2011, will be considered for
nomination to the Science Board should nominees still be needed.
ADDRESSES: All nominations for membership should be sent electronically
to CV@FDA.HHS.GOV, or by mail to Advisory Committee Oversight &
Management Staff, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103, Silver
Spring, MD 20993-0002.
FOR FURTHER INFORMATION CONTACT: Regarding all nomination questions for
membership, the primary contact is: Martha Monser, Office of the Chief
Scientist, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 32, Rm. 4286, Silver Spring, MD 20993-0002, (301) 796-4627,
email: martha.monser@fda.hhs.gov.
Information about becoming a member on an FDA advisory committee can
also be obtained by visiting FDA's Web site by using the following
link: https://www.fda.gov/oc/advisory/default.htm.
SUPPLEMENTARY INFORMATION: FDA is requesting nominations for voting
members on the Science Board.
I. General Function of the Committee
The Science Board shall provide advice primarily to the
Commissioner of Food and Drugs (the Commissioner) and other appropriate
officials on both general and specific scientific and technical issues
as well as emerging issues within the scientific community.
Additionally, the Science Board will
[[Page 72955]]
provide advice to the Agency on keeping pace with technical and
scientific advances in the fields of regulatory science; on formulating
an appropriate research agenda; and on upgrading its scientific and
research facilities to keep pace with these changes. It will also
provide the means for critical review of Agency strategic science plan
and its implementation as well as of related intramural and extramural
scientific research and training.
II. Criteria for Voting Members
Members and the Chair are selected by the Commissioner or designee
from among authorities knowledgeable in the fields of food safety,
nutrition, chemistry, pharmacology, toxicology, clinical research, and
other scientific disciplines. Members shall represent academia and
industry. The Science Board may include one technically qualified
member, selected by the Commissioner or designee, who is identified
with consumer interests and is either recommended by either a
consortium of consumer oriented organizations or other interested
persons. The Science Board may also include technically qualified
federal members. FDA is currently specifically seeking persons
knowledgeable in the fields of pharmacology, translational and clinical
medicine, toxicology, clinical research and related biostatistics,
public health and epidemiology, international public health and
regulation, product safety, product manufacturing sciences and quality
or other scientific areas relevant to FDA regulated products such as
systems biology, advanced scientific informatics, nanotechnology, food
sciences, medical devices and combination products.
III. Nomination Procedures
Any interested person may nominate one or more qualified persons
for membership on the Science Board. Self nominations are also
accepted. Nominations shall include the name of the committee, complete
curriculum vitae of each nominee, and their current business address
and telephone number and email address if available. Nominations must
specify the advisory committee for which the nominee is recommended.
Nominations must also acknowledge that the nominee is aware of the
nomination, unless self nominated. FDA will ask potential candidates to
provide detailed information concerning such matters as financial
holdings, employment, and research grants and/or contracts.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14 relating to advisory committees.
Dated: November 21, 2011.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2011-30415 Filed 11-25-11; 8:45 am]
BILLING CODE 4160-01-P